BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cole BA, Clapcote SJ, Muench SP, Lippiat JD. Targeting KNa1.1 channels in KCNT1-associated epilepsy. Trends Pharmacol Sci 2021;42:700-13. [PMID: 34074526 DOI: 10.1016/j.tips.2021.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu R, Sun L, Wang Y, Wang Q, Wu J. New use for an old drug: quinidine in KCNT1-related epilepsy therapy. Neurol Sci 2022. [DOI: 10.1007/s10072-022-06521-x] [Reference Citation Analysis]
2 Miziak B, Czuczwar SJ. Approaches for the discovery of drugs that target K Na 1.1 channels in KCNT1-associated epilepsy. Expert Opinion on Drug Discovery 2022. [DOI: 10.1080/17460441.2023.2150164] [Reference Citation Analysis]
3 Wang M, Geng G, Meng Y, Zhang H, Gao Z, Shi J. Long-term follow-up of vagus nerve stimulation in drug-resistant KCNT1-related epilepsy: a case presentation. Acta Epileptologica 2022;4:34. [DOI: 10.1186/s42494-022-00105-0] [Reference Citation Analysis]
4 M Qunies A, A Emmitte K. Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies. Pharm Pat Anal 2022. [PMID: 35369761 DOI: 10.4155/ppa-2022-0002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tobin WF, Weston MC. Excess interictal activity marks seizure prone cortical areas and mice in a genetic epilepsy model.. [DOI: 10.1101/2021.12.23.473545] [Reference Citation Analysis]